Deferoxamine therapy for intracerebral hemorrhage.
Intracerebral hemorrhage (ICH) is a subtype of stroke with very high mortality. Experiments have indicated that clot lysis and iron play an important role in ICH-induced brain injury. Iron overload occurs in the brain after ICH in rats. Intracerebral infusion of iron causes brain edema and neuronal death. Deferoxamine, an iron chelator, is an FDA-approved drug for the treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent anemia. Deferoxamine can rapidly penetrate the blood-brain barrier and accumulate in the brain tissue in significant concentration after systemic administration. We have demonstrated that deferoxamine reduces ICH-induced brain edema, neuronal death, brain atrophy, and neurological deficits. Iron chelation with deferoxamine could be a new therapy for ICH.
Hua
Y
Y
Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109-2200, USA.
Keep
R F
RF
Hoff
J T
JT
Xi
G
G
D000818:Animals; D001929:Brain Edema / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D016923:Cell Death; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D017262:Siderophores / Q000627:therapeutic use*
D017262:Siderophores; D003676:Deferoxamine